OncoMatch/Clinical Trials/NCT05281471
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Is NCT05281471 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including olvimulogene nanivacirepvec and Platinum chemotherapy: carboplatin (preferred) or cisplatin for platinum-resistant ovarian cancer.
Treatment: olvimulogene nanivacirepvec · Platinum chemotherapy: carboplatin (preferred) or cisplatin · Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin · Bevacizumab (or biosimilar) — The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Grade: 23 (figo)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, cisplatin)
Platinum-resistant or -refractory disease based on platinum-free interval (PFI) from the last dose of the most recent platinum-based line of therapy (must have received a minimum of 2 doses of platinum in that line) to subsequent disease progression based on radiological assessment. Platinum-refractory: PFI of < 1 month (including disease progression while on platinum-based therapy). Platinum-resistant: PFI of 1-6 months.
Must have received: anti-VEGF therapy (bevacizumab)
Received prior bevacizumab (or biosimilar) treatment.
Cannot have received: virus-based gene therapy or cytolytic virus
Received prior virus-based gene therapy or therapy with cytolytic virus of any type.
Cannot have received: chemotherapy
Exception: within 4 weeks prior to planned treatment
Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.
Cannot have received: radiotherapy
Exception: within 4 weeks prior to planned treatment
Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.
Cannot have received: anti-cancer biologic therapy
Exception: within 4 weeks prior to planned treatment
Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate renal, hepatic, bone marrow function, adequate coagulation tests, adequate immune function by lymphocyte count.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of South Alabama, Mitchell Cancer Institute · Mobile, Alabama
- University of Arizona Cancer Center · Tucson, Arizona
- City of Hope · Duarte, California
- UC San Diego Health - Moores Cancer Center · La Jolla, California
- Hoag Gynecologic Oncology · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify